Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antimüllerian hormone levels are lower in BRCA2 mutation carriers.

Fertility and sterility - 1 May 2017

Johnson Lauren, Sammel Mary D, Domchek Susan, Schanne Allison, Prewitt Maureen, Gracia Clarisa

Abstract excerpt

OBJECTIVE: To compare antimüllerian hormone (AMH) levels in women at high risk for hereditary breast and ovarian cancer compared with healthy low-risk control women. DESIGN: Prospective cohort. SETTING: Not applicable. PATIENT(S): Reproductive-age women with a uterus and both ovaries were analyzed in four groups: BRCA1 mutation carriers, BRCA2 carriers, BRCA-negative women, and low-risk controls. INTERVENTION(S):...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Mullerian Hormone
Share to BRCA2 Protein
Share to Comorbidity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Down-Regulation

Share to Infertility, Female

Share to Ovarian Neoplasms

Share to Pennsylvania

Share to Reference Values

Source

Open in PubMed Open full text

Identifiers

PMID: 28476184
DOI: 10.1016/j.fertnstert.2017.03.018
PMCID: PMC5531590

Genes

AMH
BRCA2
BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antimüllerian hormone levels are lower in BRCA2 mutation carriers.PMID 28476184Read ↗

BRCA1 germline mutations may be associated with reduced ovarian reserve.Semantic proximity Read ↗

Serum AMH levels in healthy women fromBRCA1/2mutated families: are they reduced?Semantic proximity Read ↗

Use of exogenous hormones in those at increased risk for breast cancer: contraceptive and menopausal hormones in gene carriers and other high-risk patients.Semantic proximity Read ↗

Association of BRCA1 Mutations with Impaired Ovarian Reserve: Connection Between Infertility and Breast/Ovarian Cancer Risk.Semantic proximity Read ↗

Ovarian reserve of women with and without BRCA pathogenic variants: A systematic review and meta-analysis.Semantic proximity Read ↗

BRCA1/2 genes mutations, ovarian reserve and female reproductive outcomes: a systematic review of the literature.Semantic proximity Read ↗

The Impact of BRCA1- and BRCA2 Mutations on Ovarian Reserve Status.Semantic proximity Read ↗

Association of BRCA Mutations and Anti-müllerian Hormone Level in Young Breast Cancer PatientsSemantic proximity Read ↗

Association of Germline BRCA Pathogenic Variants with Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level DataSemantic proximity Read ↗

Effects of BRCA gene mutation on female reproductive potential: A systematic review.Semantic proximity Read ↗

Menopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2.Semantic proximity Read ↗

Genome-wide association study meta-analysis identifies three novel loci for circulating anti-Müllerian hormone levels in womenSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.